Onco-Targets – Making loss of SFRP tumour suppressor function druggable
The invention discloses molecules, which are activated,
when function of Secreted Fizzled Related Protein 1 (SFRP1) is lost. SFRP1 is known to have tumour suppressor function and its loss is associated to tumour progression and poor survival. Access to the signalling pathways regulated by SFRP1 leads to novel targets for cancer therapy and diagnosis. Such druggable targets open the route to screening of small molecules and design of monoclonal antibodies, thereby enabling the development of innovative oncological treatments as well as new diagnostic markers.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…
